Editas, Juno Collaborate on T Cell Genome Editing for Therapies
News May 28, 2015
The firms will pursue three research programs combining Editas' genome editing technologies, including CRISPR/Cas9, with Juno's immunotherapies.
"Editas' disruptive genome editing technology may unlock the ability of CAR T and TCR technologies to address a much wider range of cancers," Juno CEO Hans Bishop said in a statement. He added that the firm was encouraged by the clinical results seen so far with its T cell products.
Under the terms of the agreement, Juno will pay Editas an upfront payment of $25 million and up to $22 million in research support over the next five years across the three programs. Editas is also eligible to receive future research, regulatory, and commercial sales milestones in excess of $230 million for each program. Following the approval of any products resulting from the alliance, Editas is also eligible to receive tiered royalties.
Juno is the latest therapeutics firm to enter the CAR T cell arena. Pfizer, Novartis, and Janssen have all established relationships with genome editing firms, such as Cellectis and Intellia Therapeutics, to drive development of their CAR T cell programs.
Cambridge, Massachusetts-based Editas has secured licenses to intellectual property rights for CRISPR/Cas9 and transcription activator-like effector nucleases (TALENs) from Massachusetts General Hospital, Duke University, Harvard University, and the Broad Institute.
Largest Genetic Study of Osteoarthritis Advances ResearchNews
Osteoarthritis is a complex disease, and the genetic basis of the disease has proved difficult to pin down. A new study from the Sanger Institute provides much-needed hope.READ MORE
Switch Discovered to Convert Blood Vessels to Blood Stem Cells During Embryonic DevelopmentNews
Findings could aid research into creating new blood cells for transplants and understanding cancer metastasis.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018